Atossa Therapeutics Inc. (NASDAQ:ATOS) traded with an addition of $0.01 to $1.42 on Friday, an upside of 0.82 percent. An average of 1,613,134 shares of common stock have been traded in the last five days. There was a fall of -$0.0829 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 2,775,059 shares traded, while the 50-day average volume stands at 3,037,967.
ATOS stock has decreased by -26.18% in the last month. The company shares reached their 1-month lowest point of $1.3900 on 01/14/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $1.13 and a high of $9.80 in 52 weeks. It has reached a new high 2 times so far this year and lost -11.88% or -$0.1529 in price. In spite of this, the price is down -85.49% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
196 days have passed since Atossa Therapeutics Inc. (ATOS) last reported insider trading activity. WEAVER GREGORY L, who is Director, most recently acquired $107,497 shares at $5.58 per share on Jul 02.
Atossa Therapeutics Inc. (ATOS) has a trailing price-to-earnings (P/E) ratio of 32.40 for the broader industry and 27.85 for the sector. The stock’s beta is 1.98. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.27.
The quick ratio of Atossa Therapeutics Inc. for the three months ended September 29 was 85.30, and the current ratio was 85.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Atossa Therapeutics Inc.’s return on assets was -23.50%. For the broader industry, ROE averaged -38.78 over the past year.
The company posted a net income of -$5.2 million in the quarter, while revenues were grew 32.88%. The analyst consensus anticipated Atossa Therapeutics Inc.’s latest quarter earnings to come in at -$0.04 per share, but it turned out to be -$0.04, a 0.00% surprise. Shareholders own equity worth $126.62 million.
From a technical analysis perspective, let’s take a brief look at Atossa Therapeutics Inc. (ATOS) price momentum. RSI 9-day as of the close on 13 January was 31.52%, suggesting the stock is Neutral, with historical volatility in this time frame at 55.90%.
As of today, ATOS’s price is $1.4774 -5.42% or -$0.0829 from its 5-day moving average. ATOS is currently trading -23.84% lower than its 20-day SMA and -60.46% lower than its 100-day SMA. However, the stock’s current price level is -49.05% below the SMA50 and -33.00% below the SMA200.
The stochastic %K and %D were 8.81% and 11.38%, respectively, and the average true range (ATR) was 0.1130. With the 14-day stochastic at 13.93% and the average true range at 0.1218, the RSI (14) stands at 32.04%. The stock has reached -0.0762 on the 9-day MACD Oscillator while the 14-day reading was at -0.1215.
Maxim Group launched coverage on Atossa Therapeutics Inc. (NASDAQ: ATOS) in its analyst report released on January 26, 2018. The firm assigned the stock a a Buy rating. The consensus rating for Atossa Therapeutics Inc. (ATOS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ATOS, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ATOS’s price target for the next 12 months?
Analysts predict a range of price targets between $8.75 and $8.75, with a median target of $8.75. Taking a look at these predictions, the average price target given by analysts for Atossa Therapeutics Inc. (ATOS) stock is $8.75.